AI assistant
Vir Biotechnology, Inc. — Director's Dealing 2021
Feb 18, 2021
32538_dirs_2021-02-18_835b6340-0b99-4f79-851e-6ed4890e1688.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2021-02-16
Reporting Person: SCANGOS GEORGE A (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-16 | Common Stock | A | 111000 | $0.00 | Acquired | 4609559 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-16 | Stock Option (Right to Buy) | $67.38 | A | 222000 | Acquired | 2031-02-15 | Common Stock (222000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 115000 | Indirect |
| Common Stock | 1907329 | Indirect |
Footnotes
F1: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
F3: The shares are held in the name of the George A. Scangos 2018 Annuity Trust dated August 30, 2018, of which the reporting person and his spouse are Trustees.
F4: 1/4 of the shares subject to the stock option vest and become exercisable on February 16, 2022, and the remainder vest in 36 equal monthly installments thereafter.